Servier is the leading French independent pharmaceutical company, present in 146 countries with over 21 400 employees and a turnover for 2014 of 4 billion euros.
25 percent of Servier’s annual turnover is reinvested in Research & Development, reflecting the company’s dedication to its research mission of innovation and discovery to treat unmet medical needs.
There are no shareholders, and no dividends are distributed from Servier’s turnover.
The main therapeutic areas for which Servier’s research is renowned are oncology, cardiology, metabolism, neuropsychiatry and rheumatology.
30 innovative medicines have been developed from in-house research since the company’s beginnings in 1954, the last three of which are each first of their therapeutic class.
Servier is currently collaborating with over 30 public and private research organizations throughout the world, including many biotech companies who chose to work with Servier among a large number of candidate companies.
68% of Servier’s medicines are produced in France. As 92% of Servier medicines are prescribed outside France, Servier thus contributes 46% of the positive commercial balance in favor of exportation in the pharmaceutical sector in France.
Servier is reputed for staff care, with particular attention to career evolution within the group such that staff turnover at Servier is significantly lower than the national average.
Contact details
Address:
15th Fl., Ploenchit Center Bldg., 2 Sukhumvit Rd., Klongtoey, Bangkok, Thailand 10110
Tel: (02) 656 8388
website: http://www.servier.com/
Servier Thailand’s general manager discusses the company’s competitive role in Thailand despite market challenges, the company’s ability to remain innovative and successful regardless of Thailand’s changing policies and Servier’s unique…
Thailand boasts one of the most attractive business and investment environments in the ASEAN region, and pharmaceutical companies implanted in the country benefit from a highly-skilled workforce and enabling infrastructure.…
Thailand is becoming an increasingly attractive location for pharma companies to conduct clinical trials, with multinationals such as Novo Nordisk and Boehringer Ingelheim conducting more and more of their global…
Diabetes affects more than eight percent of the Thai population, a number that is on the rise, and nearly half of these cases remain undiagnosed. In light of this epidemic,…
Dr Kumthorn Malathum, president of the Infectious Disease Association of Thailand, shares his insight on the issue of infectious disease in the country and the need to develop collaboration in…
Karri Kivela, executive director of the European Association for Business and Commerce (EABC) in Thailand outlines the organization’s mains activities, the ease of doing business for European companies in Thailand,…
Dr Armin Wiesler, general manager and head of Human Pharma at Boehringer Ingelheim (Thai) Ltd., explores how the affiliate has managed to achieve market-leading growth rates and addressed the challenges…
Under Thailand’s Universal Coverage Scheme, Thai citizens at every stage of life are entitled to essential health services and 99% of its population are currently covered. This year, not resting…
As the general manager of Menarini Thailand, Thomas Scott Birsinger shares the importance of the Thai affiliate within the company’s operations in the region. He also describes its efforts to…
Brijesh Sawlani, general manager for North ASEAN Thailand, Myanmar and Indochina at bioMérieux, discusses current opportunities for the Thai affiliate, the competitive landscape in Thailand, his key strategic objective to…
Dr Jadej Thammatacharee, deputy secretary general of the Thai National Health Security Office (NHSO), outlines the evolution of Thailand’s universal healthcare coverage program, the challenges inherent in its implementation, and…
Sukanya Uerchuchai, executive director of the Franco-Thai Chamber of Commerce, introduces one of the most dynamic European Chambers in Thailand, highlights the trade between Thailand and France, and explains the…
John Dawber, vice president and general manager of Novo Nordisk Thailand, offers his first impressions of the Thai market since moving from Japan. Dawber explains the current challenges and areas…
See our Cookie Privacy Policy Here
